Better T cell therapies.
Safer. Faster.
OUR PLATFORM
Unified T cell receptor discovery and safety validation in a single high-throughput, cell-based assay platform
Immfinity’s high-throughput, cell-based platform profiles T cell receptors (TCRs) across vast epitope landscapes using real immune synapse biology.
By combining antigen validation, functional screening, and and proteome-wide cross-reactivity profiling in a single workflow, we help teams de-risk candidates early and advance safer TCR therapies to the clinic—faster.
Developing TCR-based immunotherapies brings a unique set of scientific and safety challenges.
TCRs are nature’s most precise antigen recognition system, capable of distinguishing between healthy and diseased cells. But translating this precision into safe, effective therapies is difficult. Even low-level or unexpected antigen recognition can lead to serious safety risks, which are often revealed too late in development.
To succeed, teams must:
Identify novel, therapeutically relevant TCRs with strong and specific disease-targeting potential
Detect and eliminate off-target and cross-reactive responses early to protect patients and avoid costly late-stage failures
This is where Immfinity comes in.
Our platform evaluates TCRs in biologically relevant, live-cell systems—integrating discovery and safety validation from the start—so teams can make confident decisions earlier and advance only the safest, most promising candidates.
With Immfinity, you see the targets your T cells recognize, empowering you to advance the next generation of lifesaving medicines.
Detect Autoreactivity
Profile the self-antigen landscape to ensure therapeutic TCRs in oncology are selective and safe.
Unravel mechanisms of autoimmunity by revealing the epitopes of self-reactive T cells.
Discover Novel TCRs
Start finding TCRs against sets of high-value epitope targets before committing to one.
Screen libraries made of personalized cancer neo-antigens to discover custom therapeutic TCRs.
Map & Discover Epitopes
Perform rapid T cell epitope discovery to develop potent vaccines—fast.
Map T cell epitopes in engineered therapeutic proteins to make your biologics invisible to the adaptive immune system.
Monitor Immunity
Characterize the strength and coverage of T cells activated by new vaccines or checkpoint inhibitor drugs.